

Index

- (+)-Desmethyl-sibutramine, 1193
- (+)-Didesmethyl-sibutramine, 1193
- (+)-N-Desmethylzopiclone, 1055
- (R)-Oxaprotiline, 1068
- (R)-Tofisopam, 1064
- (R)-Zacopride, 1061
- (S)-Tofisopam, 1055
- 163090, 1056
- 2-hydroxyimipramine, 176
- 31264-RP, 1065
- 3-2,4 dimethoxy benylidene, 429
- 597599, 1063
- 5-HT_{1A} antagonists, 116, 117, 250
- 5-HT_{2A} antagonists, 117, 493, 553
- 5-HT_{2C} antagonists, 118, 120
- 5-HT_{2C} ligands, 120
- 5-HT₆ ligands, 122, 123
- 5-HT₇ ligands, 120, 121
- 644784, 580, 582
- A-77000, 1067
- Abaperidone, 579, 581
- ABT-089, 1192, 1193
- AC-5216, 251, 1062
- ACP-103, 429, 580, 583
- ACPC, 250, 253
- ACR-16, 579, 582
- Adatanserin, 1059
- ADD, 1091, 1130, See ADHD
- ADHD**, 176, 181, 392, 733, 1091, 1092, 1094, 1095, 1096, 1097, 1098, 1099, 1100, 1105, 1106, 1107, 1108, 1110, 1111, 1112, 1113, 1114, 1115, 1116, 1117, 1118, 1119, 1120, 1121, 1122, 1123, 1124, 1125, 1126, 1127, 1128, 1129, 1130, 1131, 1132, 1133, 1134, 1137, 1138, 1139, 1140, 1141, 1142, 1143, 1144, 1145, 1155, 1156, 1160, 1161, 1163, 1164, 1165, 1166, 1167, 1169, 1170, 1171, 1172, 1173, 1174, 1175, 1176, 1177, 1183, 1184, 1185, 1187, 1189, 1192
- Adult cases, 1124, 1125, 1127
- Classification, 1092
- Comorbidity, 1110, 1111
- Costs, 1112
- Definition, 1091, 1105, 1106, 1107, 1108
- Diagnosis, 1099, 1127, 1128, 1129, 1130, 1132
- Epidemiology, 1108, 1110
- Etiology, 1095, 1114
 - Environment, 1095, 1115, 1116, 1117, 1118
 - Genetics, 1096, 1097, 1098, 1114, 1115, 1158, 1159, 1161, 1164, 1167, 1168, 1171, 1174, 1175
- Neurobiology, 1155, 1156
- Neurochemistry, 1156
 - Dopamine, 1157, 1158, 1161, 1162, 1163, 1164, 1165, 1166, 1167, 1175
 - Noradrenaline, 1168, 1169, 1170, 1171, 1172, 1173
 - Serotonin, 1173, 1174
 - SNAP-25, 1175, 1176
- Pathophysiology, 1118
 - Electrophysiology, 1121
 - Executive functions, 1118
 - Neuroimaging, 1119, 1120
- Symptoms, 1122, 1123, 1124
- Treatment, 1133
 - Behavioral therapy, 1142, 1143

- Multimodal treatment programs*, 1144
- Non-stimulants*, 1138, 1139, 1140, 1141, 1142
- Psychostimulants*, 1134, 1135, 1136, 1137, 1176
- Adinazolam*, 251, 1066
- ADX-10059*, 1056
- AFQ-056*, 1056
- AFX-221*, 1192
- AGN-2979*, 1060
- Agomelatine*, 129, 252, 261
- Agoraphobia*, 620, 621, 624, 646, 807, 881, 884, 888
- Ainazolam*, 260
- Alnespirone*, 250, 255, 1060
- Alprazolam**, 77, 89, 951, 953
 - Synthesis*, 951, 952, 953
 - Use, PK and Metabolism*, 953
- Amantadine*, 98
- Amarin*, 130, 249, 251
- Amibegron*, 1068
- Amineptine**, 79, 192, 193
 - Synthesis*, 193
 - Use, PK and Metabolism*, 193
- Aminoglutetimide*, 97
- Amisulpride**, 377, 403, 423, 491, 493, 577, 578
 - Synthesis*, 577
 - Use, PK and Metabolism*, 578
- Amitriptyline**, 74, 75, 79, 113, 174, 181, 185
 - Synthesis*, 174
 - Use, PK and Metabolism*, 174
- Amoxapine**, 79, 190, 191
 - Synthesis*, 190
 - Use, PK and Metabolism*, 190
- Ampakine*, 251
- Animal models**
 - Construct validity*, 144, 450, 924
 - Ecological validity*, 924
 - Etiological validity*, 924
 - Face validity*, 143, 924
 - Genetic validity*, 924
 - Predictive validity*, 143, 450, 924
 - Reliability*, 450, 924
- Animal models of anxiety**, 669, 762, 926, 937
 - Conditioned*
 - Conflict tests*, 935
 - Fear potentiated startle*, 934
 - Shock-induced freezing*, 934
 - Shock-induced ultrasonic vocalizations*, 936
 - Shock-probe burying*, 935
 - Drug abuse*, 693
 - Implication for drug discovery*, 940
 - Unconditioned*
 - Elevated plus maze*, 930
 - Hole board*, 932
 - Light/dark transitions*, 929
 - Mouse defense test battery*, 933
 - Novelty-suppressed feeding task*, 933
 - Open field paradigm*, 928
 - Social interaction*, 931
 - Zero plus maze*, 930
- Animal models of depression**, 145
 - Chronic mild stress*, 148
 - Chronic severe stress*, 148
 - Conditioned place preference*, 156
 - Forced swimming test*, 151
 - Genetic models*, 158
 - Intracranial self-stimulation*, 154
 - Learned helplessness*, 146
 - Olfactory bulbectomy*, 145
 - Social loss and deprivation*, 156
 - Sucrose preference*, 155
 - Tail suspension test*, 152
 - Water despair*, 151
 - Withdrawal from psychostimulants*, 150

Animal models of schizophrenia, 450

Complexity, 449, 450

Genetic models, 468

Dopaminergic system, 471

Glutamatergic system, 470

Others, 472

Neurodevelopmental models, 464

Disruption of neurogenesis, 467

Neonatal hippocampal lesion, 465

Perinatal infection, 468

Perinatal malnutrition, 468

Pharmacological models, 453

Dopaminergic agonists, 459

NMDA/glutamate antagonists, 453

Serotonergic agents, 461

ANPH-102, 1063

Anticonvulsivants, 97

Antidepressants, 22, 68, 73, 87, 88, 129, 906, 909, 1006, 1138, 1189

Basic aspects, 69, 111

Diversity, 73, 112

Efficacy, 71

Information to the patient, 70

Interactions, 76

Maintenance therapy, 71

Mechanism of action, 68

Response-predicting factors, 93

Side-effects, 74

Treatment combination, 99

Treatment optimization, 95

Treatment potentiation, 95

Treatment switching, 99

Treatment-resistant, 94

Withdrawal, 72

Antipsychotics, 375, 389

Basic aspects, 375, 389

CB₁ antagonists, 428

D₂/D₃ only hypothesis, 423

D₄ antagonists, 427

Glutamatergic neurotransmission, 425

Muscarinic/nicotinic receptors, 428

NK₃ antagonists, 427

Non-pharmacological treatment, 377

NTS1 antagonists, 428

Rapid dissociation, 422

Role of D₂ partial agonism, 424

Anxiety

Agoraphobia, 620, 624, 646

Anatomy of obsessive-compulsive disorder, 726, 732

Benzodiazepines in posttraumatic stress disorder, 714

Biochemistry of obsessive-compulsive disorder, 725

Catecholamines in posttraumatic stress disorder, 710

Childhood anxiety, 637, 657

Cholecystokinin and memory, 850

Cholecystokinin in panic disorder, 723

Classification, 619, 881

Cognition in childhood anxiety, 776

Diagnosis

Generalized anxiety disorder, 887

Obsessive-compulsive disorder, 891

Panic disorder, 884

Social phobia, 889

Specific phobia, 890

Drug abuse and animal models, 693

Drug abuse and anxiety, 685

Generalized anxiety disorder, 692

Genetics, 696

Neurobehavioral mechanisms, 697

Obsessive-compulsive disorder, 691

Panic disorder, 685

Personality traits, 695

Posttraumatic stress disorder, 687

Social phobia, 689

Early stress in childhood anxiety, 769

- Electroencephalography in generalized anxiety disorders*, 783
- Epidemiology*, 645
 - Agoraphobia*, 646
 - Childhood anxiety*, 657
 - Generalized anxiety disorder*, 651, 886
 - Mixed anxiety–depressive disorder*, 655
 - Obsessive–compulsive disorder*, 652, 890
 - Panic disorder*, 646, 882
 - Posttraumatic stress disorder*, 653
 - Social phobia*, 648, 888
 - Specific phobia*, 650, 889
- Etiology*, 667
 - Environment and genetics*, 676
 - Generalized anxiety disorder*, 886
 - Genetics*, 673, 674, 675
 - Obsessive–compulsive disorder*, 890
 - Panic disorder*, 883
 - Specific phobia*, 890
 - Stress*, 667
 - Stress and HPA*, 668, 669, 671
- GABA-Benzodiazepines in panic disorder*, 722
- GABAergic and cholinergic interactions*, 853
- Generalized anxiety disorder*, 628, 651, 692, 885, 886, 887
- Genetics*, 673, 674, 696
- Glutamate and memory*, 852
- Hippocampal dissociations*, 855
- HPA axis in posttraumatic stress disorder*, 711
- Individual differences*, 860
- Management*
 - Generalized anxiety disorder*, 887
 - Obsessive–compulsive disorder*, 892
 - Panic disorder*, 885
 - Social phobia*, 889
 - Specific phobia*, 890
- Maltreatment in childhood anxiety*, 769
- Memory bias*, 808
- Memory bias in generalized anxiety disorder*, 817
- Memory bias in obsessive–compulsive disorder*, 814
- Memory bias in panic disorder*, 810
- Memory bias in posttraumatic stress disorder*, 816
- Memory bias in social phobia*, 812
- Memory disturbances*, 819
- Memory processes*, 807
- Mixed anxiety–depressive disorder*, 636, 655
- Neurobiology of anxiety–depression disorder*, 784
- Neurobiology of childhood anxiety*, 761, 762, 767, 768, 769, 775, 776
- Neurobiology of generalized anxiety disorder*, 777
- Neurobiology of generalized anxiety disorders*, 778, 782, 783
- Neurobiology of obsessive–compulsive disorder*, 725, 726, 728, 732
- Neurobiology of panic disorder*, 717, 718, 719, 720, 721, 722, 723
- Neurobiology of posttraumatic stress disorder*, 709, 710, 711, 713, 714, 715
- Neurobiology of social phobia*, 734, 735, 739, 740, 742
- Neurochemistry of childhood anxiety*, 762, 767, 768
- Neurochemistry of generalized anxiety disorders*, 778
- Neurochemistry of panic disorder*, 718
- Neuroendocrinology and neurochemistry of social phobia*, 735
- Neuroimaging in generalized anxiety disorders*, 782
- Neuroimaging in panic disorder*, 723
- Neuroimaging in posttraumatic stress disorder*, 715
- Neuroimaging in social phobia*, 739
- Neuronal plasticity*, 857

- Neuropsychology of obsessive–compulsive disorder*, 728
- Neuropsychology of social phobia*, 740
- Neuropsychology of posttraumatic stress disorder*, 715
- Noradrenaline in panic disorder*, 719, 721
- Obsessive–compulsive disorder*, 630, 652, 691, 890, 891, 892
- Panic attack*, 619, 882
- Panic disorder*, 622, 646, 685, 882, 883, 884, 885
- Posttraumatic stress disorder*, 633, 653, 671, 687
- Prefrontal cortex*, 847, 856
- Serotonine in panic disorder*, 720, 721
- Serotonine in posttraumatic stress disorder*, 713
- Sex differences*, 862
- Sex differences in childhood anxiety*, 775
- Social costs*, 658
- Social phobia*, 626, 648, 689, 888, 889
- Specific phobia*, 625, 650, 889, 890
- Stress response*, 667, 668, 669, 856, 857, 860, 862
- Treatment*
- 5-HT_{1A} agonists*, 900, 904
 - Antidepressants*, 897, 902, 909, 911, 914
 - Benzodiazepines*, 899, 903, 907, 910, 912
 - Generalized anxiety disorder*, 902, 903, 904
 - Obsessive–compulsive disorder*, 914
 - Overview*, 896
 - Panic disorder*, 908, 909, 910
 - Posttraumatic stress disorder*, 911, 912, 913
 - Prevention of posttraumatic symptoms*, 913
- Social phobia*, 905, 907
- Specific phobia*, 908
- Working memory*, 847
- AP-521*, 1060
- Aripiprazole**, 377, 403, 404, 424, 491, 493, 571, 572, 1163
- Synthesis*, 572
 - Use, PK and Metabolism*, 572
- Artosisopam*, 1064
- Asenapine*, 250, 259, 429, 579, 585
- Atomoxetine**, 1141, 1142, 1183, 1189
- Synthesis*, 1189, 1190
 - Use, PK and Metabolism*, 1189
- Attention deficit hyperactivity disorder*. *See* ADHD
- Atypical antidepressants*, 112, 116
- Atypical antipsychotics**, 96, 401, 403, 493, 549, 553, 577
- 5-HT_{2A/D2} hypothesis*, 403
 - Role of 5-HT_{1A}*, 409
 - Role of 5-HT_{2C}*, 414
 - Role of 5-HT₆/5-HT₇*, 416
 - Role of α_1 -adrenoceptor*, 417
 - Role of α_2 -adrenoceptor*, 420
- AV-608*, 1061
- AVE-1625*, 580, 584
- Azamianserin*. *See* Mirtazapine
- Basolateral amygdala*, 843
- Bay-q-7821*, 1066, 1067
- Befetupitant*, 1063
- Benperidol**, 491, 492, 522
- Synthesis*, 522
 - Use, PK and Metabolism*, 522
- Benzodiazepines**, 88, 896, 900, 904, 917, 933, 934, 936, 951, 961, 1061, 1064
- Adverse events*, 89
 - Interactions*, 90
 - Management*, 90
 - Overdose*, 90
 - Pharmacokinetics*, 89
 - Risk of dependence*, 90
- Bifeprunox*, 250, 259, 403, 429, 580, 585
- Binsopirone*, 1052

- Bipolar disorder*, 3, 9
- Bis(olanzapine)*, 579, 585
- BL-1020*, 580, 582
- BLA, XXXIII*, 835, 836, 837, 839, 840, 841, 842, 843, 844, 846, 847, 848, 852, See *Basolateral amygdala*
- Blonanserin*, 579, 586
- BMS-562086*, 250, 255
- BMV-13805*, 1065
- Bretazenil*, 1066
- BRL-46470*, 1058
- BRL-46470A*, 1060
- Brofaromine*, 251, 259
- Bromantan*, 1062
- Bromantane*, 1062
- Bromazepam**, 89, 985, 987
- Synthesis*, 986, 987, 988
- Use*, 987
- Bromocryptine*, 98
- Bromperidol**, 491, 492, 541
- Synthesis*, 541
- Use, PK and Metabolism*, 541
- Brotizolam**, 970, 973
- Synthesis*, 970, 971, 972
- Use and PK*, 973
- BTG-1501*, 1060
- BTG-1640*, 1053
- Bupropion**, 242, 243, 1139
- Synthesis*, 242
- Use, PK and Metabolism*, 243
- Buspirone**, 98, 900, 904, 917, 1002, 1003
- Synthesis*, 1002
- Use, PK and Metabolism*, 1003
- Butriptyline**, 180
- Synthesis*, 180
- Use*, 180
- CAM-958*, 1060
- Cannabidiol*, 580, 584
- Carbamazepin**, 240
- Synthesis*, 240
- Use, PK and Metabolism*, 241
- Carnosine*, 580, 584
- Carpipramine**, 491, 492, 537, 1019, 1020
- Synthesis*, 537, 1019, 1020
- Use and PK*, 1020
- Use, PK and Metabolism*, 537
- Casopitant*, 130, 251, 256, 1064
- Catatonic schizophrenia*, 301, 366
- CCK*, 723, 778, 781, 782, 850, 851, 852, See *Cholecystokinin*
- CGP-12103A*, 1068
- CGP-361A*, 1051
- CGP-608*, 1061
- CGS-15040A*, 1059
- CGS-19480A*, 1051
- CGS-19755*, 1067
- CGS-20625*, 1058
- CGS-8216*, 1051
- Chlordiazepoxide**, 89, 976, 977
- Synthesis*, 976
- Use, PK and Metabolism*, 977
- Chlorpromazine**, 376, 396, 491, 492, 495, 496, 1013, 1015
- Synthesis*, 496
- Use, PK and Metabolism*, 496
- Chlorprothixene*, 397, 491
- Cholecystokinin*, 723, 850
- CI-1043*, 1068
- CI-988*, 723, 782, 1060
- Cianopramine*, 258
- Cipralisant*, 1192, 1193
- Citalopram**, 74, 75, 114, 200, 201, 202
- Synthesis*, 200
- Use, PK and Metabolism*, 201
- CL-216303*, 1064
- Classic antipsychotics**, 498, See *Typical antipsychotics*

- Clobazam**, 89, 988
Metabolism, 988, 990
Synthesis, 988, 989
- Clomipramine**, 74, 75, 113, 184, 185, 186, 917, 1043
Synthesis, 184, 1043, 1044
Use, PK and Metabolism, 185
- Clonazepam**, 907, 954
Synthesis, 954, 955
- Clorazepate**, 995
Synthesis, 995, 996
Use, PK and Metabolism, 995
- Clorazepate, 995
- Clorgyline, 259
- Clotiazepam**, 996, 998
Synthesis, 996, 997
Use and PK, 998
- Clotiazepam, 996
- Clovoxamine, 251, 260
- Clozapine**, 377, 402, 403, 404, 417, 422, 491, 493, 549, 550, 1162
Synthesis, 550
Use, PK and Metabolism, 550
- CP-122721, 251, 256
- CP-143867, 1053
- CP-316311, 250, 255
- CP-409092, 1053
- CP-93393, 1068
- CP-93393-1, 1068
- CR-2945, 1054
- CRD-101, 581, 582
- CRF, XXXII, XLV, 23, 24, 26, 27, 67, 123, 124, 668, 669, 670, 672, 698, 699, 700, 713, 737, 762, 763, 764, 766, 767, 768, 778, 782
- CRF Antagonists, 123
- CX-516, 251, 257, 426
- CX-717, 1192, 1194
- Cyamemazine**, 491, 492, 532, 534, 1020
Synthesis, 532, 1021
Use, 532
- Cyclobenzaprine**, 1044
Synthesis, 1045, 1046, 1047
- D-13112, 1066
- Delucemine, 130, 251, 254
- Depression**
Biochemistry, 63
Classification, 52
Cronobiological hypothesis, 27
Epidemiology, 61
Etiology, 7, 10
Genetics, 10
Infectious hypothesis, 28
Introduction, 3, 51
Management, 90
Monoamine hypothesis, 14, 64
Neuroendocrine hypothesis, 23, 66
Neuroendocrinology, 66
Neuroimaging, 29
Neuropathology, 309
Neurophysiology, 29
Neuroplasticity, 31
Non-pharmacological treatment, 100
Pathogenesis, 14
Physiopathology, 63
Prevalence, 6
Sleep, 27
- Desipramine**, 77, 79, 113, 176, 181
Synthesis, 181
Use, PK and Metabolism, 181
- Destroamphetamine, 1183
- Desvenlafaxine, 252, 261, 1069
- Dextofisopam, 1064
- Dextroamphetamine**, 97, 1136, 1183, 1184
Synthesis, 1183
Use and PK, 1184

Diazepam, 77, 89, 954, 956, 959, 961

Metabolism, 961

Synthesis, 956, 957, 959, 960

Use and PK, 961

Dibenzepine, 248*Dihydroepiandrosterone*, 97*Diloxetine*, 1062*Dimetacrine*, 248**Divalproex**, 243

Synthesis, 243

Use PK and Metabolism, 244

Divaplon, 1058*DMP-904*, 250, 253*DMXB-Anabaseine*, 580, 584*DN-2327*, 1067

dopamine reuptake inhibition, 119

Dosulepin, 183

Synthesis, 183

Use, PK and Metabolism, 183

DOV-102677, 249, 252, 1193*DOV-216303*, 249, 255, 1064*DOV-21947*, 249, 252**Doxepin**, 113, 187

Synthesis, 187

Use, PK and Metabolism, 188

DP-VPA, 251, 256**Droperidol**, 491, 492, 517, 518

Synthesis, 518

Use and PK, 518

Droperidole, 397*DU-125530*, 250, 254*DU-13811*, 260*DU-29373*, 1067**Duloxetine**, 74, 86, 225, 226, 228

Synthesis, 225

Use, PK and Metabolism, 226

DVS-233, 129, 1069**Dysthymic disorder**, 3, 8

Classification, 60

Combined treatment, 103

Epidemiology, 63

Introduction, 8

Pharmacological treatment, 101, 102

Psychosocial treatment, 103

E-4424, 1059*E-6006*, 251, 253, 1062*E-6039*, 251, 253, 1062*Ebaltozan*, 1053*EGIS-5810*, 1058*EGIS-6775*, 1051*Eglumegad*, 1061*ELB-139*, 1062

Electroconvulsive therapy, 100

Elzasonan, 130, 250, 255*Emapunil*, 251, 257, 1062*EMD-56551*, 1053*EN-01*, 1062*Enciprazine*, 1066*Endixaprine*, 1057*Eplivanserin*, 1059, 1060*Eptapirone*, 1062*Escitalopram*, 114, 200, See *Citalopram**Eslicarbazepine*, 251, 260**Ethyl loflazepate**, 974, 976

Synthesis, 974, 975

Use, 976

Etifoxine, 1010, 1011

Synthesis, 1010

Use, 1011

Etizolam, 973

Synthesis, 973

Use and PK, 973

Etoperidone, 216

Synthesis, 216

Use, 216

- F-11440, 1062
F-2692, 1052
Farampator, 251, 257, 580, 583
FCE-23884, 1057
Fenobam, 1065
FG-10571, 1052
Flesinoxan, 1067
Fluoxetine, 74, 75, 77, 114, 194, 195, 197, 1189
 Synthesis, 194
 Use, PK and Metabolism, 197
Flupentixol, 376, 397, 491, 492, 523, 524, 525
 Synthesis, 524
 Use, PK and Metabolism, 524
Fluphenazine, 376, 396, 403, 491, 492, 509, 510, 1014, 1015
 Synthesis, 509, 1014, 1015
 Use, PK and Metabolism, 510
Fluspirilene, 491, 492, 530, 531
 Synthesis, 531
 Use, 531
Fluvoxamine, 74, 75, 77, 114, 202, 203
 Synthesis, 202
 Use, PK and Metabolism, 203
Folate, 98
GAD, 651, 652, 659, 673, 676, 692, 693, 721, 738, 777, 778, 779, 780, 781, 782, 783, 784, 807, 817, 881, 883, 885, 886, 887, 888, 889, 902, 903, 904, 905, 910, 917, 926, 1029, 1032, 1038, See Generalized anxiety disorder
Gedocarnil, 1052
Gepirone, 129, 250, 259, 1065
Gidazepam, 1061
Girisopam, 1058
Glemanserin, 1052
Glucocorticoid receptor, 835
Glucocorticoids, XXXV, 124, 838
Glutamatergic targets, 128
GPE, 251, 258
GR, 23, 26, 124, 130, 669, 764, 765, 766, 835, 836, 838, 840, 845, 846, 847, 848, See Glucocorticoid receptor
GSK-372475, 250, 255, 1193
guanfacine, 1138, 1140, 1170, 1194
GV-150013, 1060
GW-150013, 1060
GW-273293, 251, 257
GW-597599, 1063
GW-679769, 1064
GW-823296, 251, 253, 1056
GW-876008, 250, 253, 1056
GYKI-51189, 1058
GYKI-52322, 1051
Halazepam, 993, 995
 Synthesis, 993, 994
 Use, 995
Haloperidol, 77, 376, 397, 403, 404, 414, 491, 492, 511, 512, 513, 515
 Synthesis, 512
 Use, PK and Metabolism, 513
Harmala, 114
Hebephrenic schizophrenia, 301, 366
HPA, XXXV, XXXVI, XLV, 23, 24, 25, 26, 27, 33, 123, 124, 149, 157, 159, 668, 670, 671, 672, 677, 685, 698, 699, 709, 711, 712, 716, 735, 763, 767, 774, 778, 779, 782, 784, 854, 860, 862, 883, See Hypothalamic–pituitary–adrenal axis
Hydroxyzine, 1041, 1042
 Synthesis, 1041, 1042
 Use and PK, 1042
Hypothalamic–pituitary–adrenal axis, XXXVI, 23, 67, 123, 668, 671, 711
ICI-118551, 1065
ICI-170809, 1058
Ifooxetine, 249, 254
Iloperidone, 579, 585
Imipramine, 74, 75, 77, 79, 113, 175, 176, 917
 Synthesis, 176
 Use, PK and Metabolism, 176

- Inositol*, 98, 917
IP-456, 1068
Ipsapirone, 1066, 1067
Irindalone, 1057, 1059
Isamoltan, 1051
Isocarboxazid, 114, 235
 Synthesis, 235
 Use, PK and Metabolism, 235
Isovaleramide, 254
Itriglumide, 1054
JNJ-19567470, 131, 250, 253, 1056
Kava extract, 1050
KC-9172, 1051
Ketazolam, 89, 991, 993
 Synthesis, 992
 Use, 993
Ketoconazole, 77, 97
L-0068, 1062
L-365260, 1058
Ladasten, 1062
Lamotrigine, 246, 247, 580, 581, 586
 Synthesis, 247
 Use, PK and Metabolism, 247
LAX-101, 130, 257
LAX-201, 249, 255
Laxdale, 249
Lesopitron, 1059
Levomepromazine, 376, 491, 492, 502
 Synthesis, 502
 Use, PK and Metabolism, 502
Levoprotiline, 1068
Levosulpiride, 491, 492, 526, 527, 542, 543
 Synthesis, 542
 Use, PK and Metabolism, 543
Levotofisopam, 998, 1055
Licarbazepine, 251, 259
Lisdexamphetamin, 1194
Lisdexamphetamine, 1192
Lithium, 32, 94, 96, 112, 115, 239, 491, 492, 494
 Use and PK and Metabolism, 239
 Use, PK and Metabolism, 494
lobeline, 1192
Lobeline, 1193
Lofepamine, 74, 113, 192
 Synthesis, 192
 Use, PK and Metabolism, 192
Lonasen, 429
Lorazepam, 89, 963, 964, 965
 Synthesis, 963, 964
 Use, PK and Metabolism, 964
Lormetazepam, 89, 964, 965
 Synthesis, 965
 Use, PK and Metabolism, 965
Loxapine, 491, 492, 534, 535
 Synthesis, 534
 Use, PK and Metabolism, 535
LU-21-098, 1059
LU-21-098X, 1057
LU-28-179 HCl, 1056
Lu-31-130, 580, 582
Lu-AA-21004, 249, 252
Lu-AA-24530, 251, 254
Lu-AA34893, 1056
Lurasidone, 579, 582
LY-2140023, 580, 584
LY-277359, 1068
LY-314582, 1061
LY-354740, 1061
LY-404039, 580, 584
LY-544344, 1055
MADD, 784, 785. *See Mixed anxiety–depression disorder*
Major depressive disorder, 57, 85. *See Depression*
Manic depressive disorder. See Bipolar disorder

- MAOIs**, 22, 81, 82, 83, 84, 88, 92, 94, 100, 102, 111, 112, 113, 118, 131, 233, 237, 889, 897, 915, 1189, *See Monoamine oxidase inhibitors*
- Maprotiline**, 74, 79, 189
- Synthesis, 189
 - Use, PK and Metabolism, 190
- MCH antagonists, 126
- MCI-242, 1065
- MDL-11939, 1052
- MDL-73005EF, 1052
- ME-3127, 1062
- Mebicar**, 1039
- Synthesis, 1039
- Mecamylamine, 1192
- Medazepam**, 954, 980, 982
- Synthesis, 980, 981, 982
 - Use and PK, 982
- Medetomidine, 1057
- Medifoxamine, 251, 254
- Melitracen, 248
- Melperone**, 491, 1016
- Synthesis, 1016
 - Use, PK and Metabolism, 1016
- MEM-1003, 251, 257
- MEM-3454, 580, 582
- Memory**
- Categories, 804
 - Cholecystokinin, 850
 - Consolidation and emotions, 834
 - Glutamate, 852
 - Hippocampal dissociations, 855
 - Neurobiology, 831
 - Processes and mechanisms, 803
 - Release of stress hormones, 837, 845, 847
 - Relevance of Hippocampus, 855, 857
 - Relevance of the amygdala, 835, 836, 837, 843, 847
 - Retrieval, 845
 - Steps, 805
 - Storage, 832
 - Temporal nature, 805
- Meprobamate**, 1039, 1040
- Synthesis, 1040
 - Use, PK and Metabolism, 1040
- metanicotine, 1192
- Metanicotine, 1193
- Metapramine, 248
- Methamphetamine**, 1184, 1185
- Synthesis, 1184
 - Use, 1185
- Methamphetamine, 1184
- Methylphenidate**, 1134, 1136, 1185, 1187
- Synthesis, 1185
 - Use, PK and Metabolism, 1187
- Methylphenidate, 1185
- Metirapone, 97
- Mianserin, 74, 75, 79, 87, 229, 248
- Midazolam**, 89, 965, 968
- Metabolism, 968
 - Synthesis, 966, 967
 - Use and PK, 968
- Mifepristone**, 581, 586, 1026, 1027
- Synthesis, 1027
- Milnacipran**, 220, 221
- Synthesis, 220
 - Use and Metabolism, 221
- Miraxion, 130, 251, 257
- Mirisetron, 1053
- Mirtazapine**, 74, 87, 229, 230
- Synthesis, 230
 - Use, 230
- Mixed amphetamine salts, 1136, 1183
- MJ-13805, 1065
- MKC-242, 411, 1065
- MN-305, 1065

Moclobemide, 74, 75, 114, 237, 238, 898, 999, 1000

Synthesis, 237, 999, 1001

Use, PK and Metabolism, 237

Modafinil, 580, 585, 1140, 1192

Monoamine oxidase inhibitors, XL, 81, 112, 113, 114, 116, 233, 999

Adverse effects, 83

Indications, 83

Interactions, 82

Intoxication, 83

Mechanism of action, 82

Non-selective, 233

Pharmacokinetics, 82

Precautions, 82

Type A, 237

Mosapramine, 491, 492, 545, 546

Synthesis, 545

Use, PK and Metabolism, 546

MPV-785, 1057

NAE-086, 1053

NBI-34041, 26, 1055

ND-7001, 251, 253, 1056

Neboglamine, 250, 253, 580, 582

Nefazodone, 77, 217, 218

Synthesis, 217

Use, PK and Metabolism, 218

Nemifitide, 130, 251, 258

Nemonapride, 491, 492, 547, 548

Synthesis, 547

Use, 548

NEO-339, 1192

Nerisopam, 1051

Neurotrophins, 126

NGD-91-1, 1053

NGD-91-2, 1056

NGD-91-3, 1062

NGI-101, 1064

NGI-221, 1192

NK1 antagonists, 125

NKP-608, 1061

Noradrenaline and specific serotonergic antidepressants, 229

Noradrenaline reuptake inhibitors, XL, 87, 112, 114, 231

Norclozapine, 584

norclozapine/N-desmethylozapine, 580

Nordazepam, 990, 991, 993

Synthesis, 991

Use, PK and Metabolism, 991

Nortriptyline, 113, 182

Synthesis, 182

Use, PK and Metabolism, 182

NPS-1776, 251, 254

NRP-104, 1192, 1194

NS-2359, 255, 1193

NS-2710, 1062

Ocaperidone, 579, 582

OCD, 194, 210, 652, 653, 655, 673, 691, 692, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 737, 740, 741, 807, 814, 820, 881, 890, 891, 892, 914, 915, 916, 917, See Obsessive-compulsive disorder

O-Desmethylenlafaxine, 1069

Olanzapine, 377, 403, 404, 430, 491, 493, 559, 560, 563

Synthesis, 559

Use, PK and Metabolism, 560

Omega-3 fatty acids, 99

Ondansetron, 580, 583

ONO-2333MS, 26, 250, 253, 1056

OPC-14523, 130, 254

Opipramol, 179

Synthesis, 179

Use, 179

ORG 24448, 429

ORG 5222, 429

ORG-25935, 580, 581

ORG-33062, 1065

- ORG-34517, 251, 257
- Osemozotan, 1065
- Oxaprotiline, 250, 259
- Oxazepam**, 89, 978, 979
- Synthesis, 978, 979
- Use and PK, 979
- Oxprenolol**, 1024, 1026
- Synthesis, 1024, 1025
- Use, PK and Metabolism, 1026
- Oxycodone, 98
- Oxymorphone, 98
- Pagoclone, 1068
- Paliperidone, 579, 585, 586
- Panadiplon, 1052
- Paranoid schizophrenia, 301, 367
- Paroxetine**, 74, 75, 77, 114, 206, 208, 1190
- Synthesis, 206
- Use, PK and Metabolism, 208
- Pazinaclone, 1067
- PD**, 721, *See* Panic disorder
- PD-134308, 1060
- PD-216948, 1055
- Pemoline, 1166, 1183
- Periciazine**, 491, 492, 519, 520
- Synthesis, 519
- Use, 520
- Perospirone**, 491, 493, 570
- Synthesis, 570
- Use, PK and Metabolism, 570
- Perphenazine**, 376, 397, 491, 492, 503, 504
- Synthesis, 504
- Use, PK and Metabolism, 504
- PF-00184562, 580, 582
- PFC, 15, 29, 30, 305, 310, 312, 313, 314, 315, 318, 320, 321, 324, 325, 389, 411, 415, 417, 420, 421, 426, 430, 449, 453, 455, 457, 458, 461, 462, 464, 465, 466, 467, 729, 835, 843, 847, 848, 849, 850, 852, 856, *See* Prefrontal cortex
- PH-94B, 1063
- Phenelzine**, 74, 75, 114, 234, 917
- Synthesis, 234
- Use, PK and Metabolism, 234
- Phosphodiesterase inhibitors, 128
- Photostimulation, 100
- Piberaline, 251, 257
- Pikamilone, 1059
- Pimozide**, 376, 397, 491, 492, 528, 529
- Synthesis, 529
- Use, PK and Metabolism, 529
- Pindolol, 98
- Pipotiazine**, 491, 492, 533, 534
- Synthesis, 533
- Use, PK and Metabolism, 534
- Piricapiron, 1061
- Pramipexol, 98
- Pramipexole, 250, 255
- Prazepam**, 983
- Synthesis, 983, 984
- Prefrontal cortex, 843
- Pregabalin**, 1032, 1038
- Synthesis, 1033, 1034, 1035, 1036, 1037
- Use, 1038
- Procaine, 252, 261
- Prochlorperazine**, 397, 491, 492, 499, 500
- Synthesis, 500
- Use, PK and Metabolism, 500
- Promazine**, 491, 492, 501
- Synthesis, 501
- Use and PK, 501
- Propranolol**, 77, 1021, 1023
- Synthesis, 1021, 1022, 1023
- Use, PK and Metabolism, 1023
- Protriptyline**, 113, 186, 187
- Synthesis, 186
- Use, PK and Metabolism, 186
- PRX-00023, 129, 250, 258, 1068, 1192, 1194
- Psychosocial treatments, 101, 377, 1142

Psychostimulants, 97, 1134, 1166, 1183

Psychosurgery, 101

PTSD, 210, 653, 654, 655, 659, 668, 671, 687, 688, 689, 709, 710, 711, 712, 713, 714, 715, 716, 717, 736, 738, 761, 767, 768, 769, 770, 771, 772, 774, 807, 816, 817, 819, 820, 881, 885, 892, 911, 912, 913, 917, *See* *Panic disorder*

PW-4112, 251, 260

PW-4123, 581, 582

Quetiapine, 261, 377, 403, 404, 491, 493, 564, 565

Synthesis, 564

Use, PK and Metabolism, 565

Quinupramine, 248

R-1204, 1055

R-1678, 581, 582

R-228060, 257

R-55667, 1066

R-56413, 1057

R-673, 1064

Radafaxine, 130, 250, 255

Reboxetine, 74, 87, 231, 232

Synthesis, 231

Use, PK and Metabolism, 232

Remoxipride, 403, 491, 492, 544

Synthesis, 544

Use, PK and Metabolism, 544

Repetitive transcranial magnetic stimulation, 100

Residual schizophrenia, 301, 367

RG-2417, 1064

RGH-188, 250, 252, 580, 583

Ricasetron, 1058, 1060

Rilmazafone, 1006, 1007

Metabolism, 1007, 1008

Synthesis, 1006, 1007

Use and PK, 1007

Risperidone, 77, 377, 403, 404, 491, 493, 555, 556, 557

Synthesis, 556

Use, PK and Metabolism, 557

Ritanserlin, 408, 1066

Ro-16-6028, 1066

Ro-16-6028/000, 1066

Ro-46-2153, 1054

Ro-48-6791, 1054

Ro-48-8684, 1054

Ro-67-5930, 1063

Rolipram, 251

Romergoline, 1057

RP-31264, 1065

RP-59037, 1068

RP-62955, 1068

Ru-32698, 1058

RWJ-51204, 1062

SJ-DMZ, 1055

S-15535, 1053

S-16924, 1061

S-20098, 261

S-20499, 1060

SA-4503, 251, 256

S-adenosyl-methionine, 98

Sapropterin, 1011

Synthesis, 1011, 1012

Saredutant, 129, 251, 260, 1068

Saripidem, 1059

SAX-187, 1056

SB-163090, 250, 252

SB-243213, 1054

SB-247853, 250, 252, 1054

SB-723620, 1055

SB-773812, 580, 583

SC-48274, 1060

Schizophrenia

Affective symptoms, 358
 Attention deficit, 351
 Brain pathology, 308
 Cellular abnormalities, 313
 Classification, 300
 Cognitive deficit, 305, 347, 350, 356
 Course, 307
 Diagnosis, 300
 Dopaminergic hypothesis, 318, 369, 391
 Epidemiology, 306, 341, 360
 Etiology, 367
 Executive function, 354
 GABAergic hypothesis, 325
 Genetics, 368
 Glutamatergic hypothesis, 321, 370
 Infectious hypothesis, 372
 Introduction, 299, 335, 336
 Language disorders, 355
 Memory alterations, 352
 Negative symptoms, 345
 Neuroendocrine hypothesis, 372
 Neuroimaging, 309, 371
 Neuropsychology, 371, 391, 450
 Onset, 365
 Pathogenesis, 316
 Positive symptoms, 342
 Prognosis, 373
 Psychosocial factors, 372
 Risk factors, 361
 Semiology, 341
 Serotonergic hypothesis, 320, 370
 States, 366
 Suicide risk, 360, 363, 364
 SEB-324, 1059
 SEC-579, 1053
 Secretin, 429
 Seganserin, 1057

Selanc, 1065

Selective serotonin reuptake inhibitors, XLIV, 84, 112, 114, 193, 198, 917

Adverse events, 85

Indications, 85

Management, 84

Pharmacokinetics, 84

Serotonergic syndrome, 85

Selegiline, 114, 252, 261

Selfotel, 1067

SEP-174559, 1055

SEP-225289, 130, 250, 252

Serazapine, 1059

Serotonin and noradrenaline reuptake inhibitors, XLIV, 86, 112, 115, 220

Adverse events, 86

Indications, 86

Sertindole, 377, 403, 491, 493, 573, 574

Synthesis, 573

Use, PK and Metabolism, 574

Sertraline, 74, 75, 77, 114, 210, 211

Synthesis, 210

Use, PK and Metabolism, 211

Setiptiline, 248

SGS-518, 580, 583

SGS-742, 1192, 1193

SH-530, 1052

Simple schizophrenia, 301, 367

Siramesine, 1056

SL-65.1498, 1063

SL-651498, 1063

SL-85.0274, 1059

Sleep deprivation, 27, 100

SLV-308, 259

SLV-313, 583

SLV-314, 249, 252, 580, 581

SNRIs, 22, 86, 112, 115, 118, 131, 146, 220,
 See Serotonin and noradrenaline reuptake
 inhibitors

SP, 125, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, *See Social phobia*

SPD-465, 1192, 1194

SPD-503, 1192, 1194

SPPI-339, 1192

SR-149415, 1063

SR-41378, 1057

SR-46349B, 1060

SR-46349C, 1059

SR-48965, 1068

SR-48968, 1068

SR-489686, 1068

SR-58611, 251, 260, 1068

SR-58611A, 1068

SSR-125543, 250, 253, 1055

SSR-125543A, 26, 1055

SSR-149415, 251, 256, 1063

SSR-240600, 1063

SSR-240600C, 1063

SSR-411298, 1055

SSR-504734, 580, 581

SSRIs, 11, 19, 22, 83, 84, 85, 92, 99, 102, 111, 112, 114, 115, 117, 118, 119, 120, 126, 129, 131, 149, 151, 152, 173, 194, 195, 233, 249, 430, 508, 677, 713, 714, 720, 736, 883, 889, 892, 897, 898, 899, 902, 903, 906, 907, 908, 909, 910, 911, 912, 914, 915, 917, 933, 1139, *See Selective serotonin reuptake inhibitors*

St. John's Wort extract, 122, 251, 260

Sulpiride, 403, 423, 491, 492, 526, 527

Synthesis, 527

Use, PK and Metabolism, 527

Sultopride, 491, 492, 536, 537

Synthesis, 536

Use and PK, 537

Sunepitron, 1068

Suriclone, 1065

SX-5216, 1062

Talaglumetad, 1055

Talnetant, 429, 580, 583

Tandospirone, 249, 491, 492, 548, 1003, 1006

Synthesis, 548, 1003, 1004, 1005

Use, 548, 1006

TC-5231, 1192

TCAs, 22, 78, 79, 80, 83, 84, 85, 99, 100, 111, 112, 113, 115, 124, 129, 131, 147, 149, 151, 159, 173, 176, 178, 181, 182, 185, 186, 188, 190, 192, 193, 194, 197, 201, 203, 208, 211, 215, 216, 218, 220, 231, 233, 234, 239, 243, 245, 248, 508, 579, 897, 898, 899, 903, 909, 910, 912, 1183, 1184, *See Tricyclic antidepressants*

Teniloxazine, 251, 260

Tetrabamate, 1009

Synthesis, 1009, 1010

Thioridazine, 397, 491, 492, 506, 507

Synthesis, 506

Use, PK and Metabolism, 506

Thiothixene, 397, 491, 492, 520, 522

Synthesis, 520

Use, PK and Metabolism, 520

Tiagabine, 1029, 1031

Synthesis, 1030, 1031

Use, PK and Metabolism, 1031

Tianeptine, 248, 1017, 1018

Synthesis, 1017, 1018

Use, PK and Metabolism, 1018

Tiapride, 491, 492, 538, 539

Synthesis, 538

Use, PK and Metabolism, 539

Tofizopam, 998

Synthesis, 998, 999

Use, 998

Tolcapone, 429

Toloxatone, 238

Synthesis, 238

Use, PK and Metabolism, 238

TP-7, 1065

TPA-023, 1054

Tranlycypromine, 74, 82, 114, 236

Synthesis, 236

Use, PK and Metabolism, 236

Trazodone, 75, 88, 114, 214, 215

Synthesis, 214

Use, PK and Metabolism, 214

Tricyclic antidepressants, 78, 112, 173, 915, 1138

Adverse events, 80

Indications, 80

Intoxication, 81

Mechanism of action, 78

Pharmacokinetics, 79

Precautions, 79

Prescription, 80

Trifluoperazine, 397, 491, 492, 508, 509, 1012, 1013

Synthesis, 508, 1012

Use and PK, 509, 1013

Triflupromazine, 491, 492, 505

Synthesis, 505

Use, PK and Metabolism, 505

Triiodothyronine, 96**Trimipramine**, 113, 178

Synthesis, 178

Use and PK, 178

Tryptophan, 19, 97**TS-041**, 26, 131, 1056**TVX-Q-7821**, 1066, 1067**Typical antipsychotics**, 98, 396, 403, 492, 494

Dopamine receptors, 398

Side-effects, 400

U-41123, 1066**U-78875**, 1052**U-93385**, 1053**Umespirone**, 1051**Unipolar depressive disorder**. See Depression**Uridine**, 251, 254, 1064**Vabicaserin**, 580, 583**Vagus nerve stimulation**, 100**Valnoctamide**, 1047, 1050

Synthesis, 1047, 1048, 1049

Use and PK, 1050

Valproic acid, 244. See Divalproex**Vasopressin receptor antagonists**, 124**VEC-162**, 251, 257**Venlafaxine**, 74, 77, 86, 223, 224, 917

Synthesis, 223

Use, PK and Metabolism, 224

Veralipride, 491, 492, 540

Synthesis, 540

Use and PK, 540

Vesipitant, 251**Vestipitant**, 130, 251, 256, 1063**Vilazodone**, 250, 258**Viloxazine**, 245

Synthesis, 245

Use, PK and Metabolism, 245

Viqualine, 249, 258**Virucort**, 252, 261**VPI-013**, 130, 250, 255**WAY-100289**, 1053**WAY-100579**, 1053**WAY-181187**, 1056**WAY-SEB-324**, 1059**WAY-SEC-579**, 1053**WY-45233**, 1069**Wy-47846**, 1058**Wy-48624**, 1066**Wy-50324**, 1059**XBD-173**, 1064**XY-2401**, 580, 582**Y-22990**, 1052**Y-23684**, 1067**YKP-10A**, 130, 251, 257**YKP-1358**, 579, 581

YKP-581, 251, 254

Zalospirone, 1058

Zatosetron, 1068

Ziprasidone, 377, 403, 404, 491, 493, 566, 567, 570

Synthesis, 566

Use, PK and Metabolism, 566

ZK-91296, 1057

ZK-93423, 1051

ZM-170809, 1058

Zotepine, 491, 493, 553, 555

Synthesis, 554

Use, PK and Metabolism, 555

Zuclopenthixol, 491, 492, 516

Synthesis, 516

Use, PK and Metabolism, 516

α_2 antagonists, 118